Marvelon

Summary

Marvelon (CHEMBL1697756) is a phase-3 clinical-stage small molecule; indicated across 1 condition including premenstrual tension.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 7
• Chemistry: 606.9 Da · C42H54O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1697756
Name	Marvelon
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	62957
Molecular formula	C42H54O3
Molecular weight	606.9
InChIKey	MXBCYQUALCBQIJ-RYVPXURESA-N

SMILES: CC[C@]12CC(=C)[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CCCC[C@H]34.C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O

IUPAC name: (8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol;(8R,9S,13S,14S,17R)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol

Also known as: Marvelon, MARVELON

Patent coverage: 440 distinct patent families (752 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
premenstrual tension	2	MONDO:0004169	MONDO:0004169

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE4	3
Not specified	2
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00778999	PHASE4	COMPLETED	Predictive Factors for Ovarian Stimulation Using a Fixed Daily Dose of 200 IU Recombinant FSH (Study 142003)(P05696)
NCT01384331	PHASE4	UNKNOWN	New Treatments for Troublesome Bleeding in Implanon Users
NCT03953716	PHASE4	UNKNOWN	Traditional Chinese Medicine, Western Medicine and Low-level Light Therapy（LLLT） for Primary Dysmenorrhea（PD）
NCT00185419	PHASE3	COMPLETED	A Clinical Study on Yasmin® vs. Marvelon® in Chinese Women Requiring Contraception
NCT01256619	PHASE2	UNKNOWN	Evaluation of an Oral Contraceptive Containing 30 mg Ethinyloestradiol and 150 mg Desogestrel on Women’s Health
NCT00565240	Not specified	COMPLETED	Mid-luteal Phase Synchronization of Ovarian Folliculogenesis in Women
NCT01298128	Not specified	TERMINATED	NuvaRing vs. Oral Contraceptive Pills (OCP) for In-Vitro Fertilization (IVF) Pre-treatment

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).